The report on Myelodysplastic Syndrome Market by The report on global myelodysplastic syndrome market covers segments such as the route of administration and drug class. On the basis of the route of administration, the global myelodysplastic syndrome market is categorized into parenteral and oral. On the basis of drug class, the global myelodysplastic syndrome market is categorized into cytotoxic antibiotics, topoisomerase inhibitors, alkylating agents and others. trends analysis and forecasts up to 2024 studies the market sizes, key trends, and opportunities in the main geographies such as North America, Europe, Asia-Pacific, Rest of the World. According to the report the Global Myelodysplastic Syndrome Market is projected to grow at a CAGR in terms of value over the period of 2018-2024. The growth in the world market is primarily driven by a significant contribution by North America (Leading region) region to this market. According to the report, the global myelodysplastic syndrome market is projected to grow at a CAGR of 12.3% over the forecast period of 2018-2024.
Myelodysplastic Syndrome Treatment Market: Industry Insight
MDS is considered a type of cancer. Myelodysplastic syndromes (MDS) is a condition, that can occur when the blood-forming cells in the bone marrow become abnormal. This leads to low numbers of one or more types of blood cells. It is a rare group of disorders in which the human body is not able to produce enough healthy blood cells required by the body. Several types of tests is used to detect and diagnose the MDS. Most people who are suffering from this disease are around 65 years old or older than this, but it can also happen to younger people. It is more common in men compared to female.
Myelodysplastic Syndrome Treatment Market: Drivers and Restraints
Factors such as the growing number of the patient pool of age 50 and above, increasing mutation in treatments that cause myelodysplastic syndrome are the main drivers of the market. Government initiatives to provide target-specific treatments and favorable reimbursement policies are also expected to fuel the growth of this market in the developing countries. However, the high cost of therapeutics and low awareness about the treatments among patients in the developing countries are the restraints of the market. The ongoing research and development work to develop the new cost-effective treatment and growing demand of MDS treatment in the developing countries are expected to boost the growth of this market in the near future.
Myelodysplastic Syndrome Treatment Market: Segmentation
The Myelodysplastic Syndrome Treatment Market is segmented on the basis of the types and drug classes. On the basis of types, the global Myelodysplastic Syndrome Treatment Market is categorized into chemotherapy and immunotherapy. Chemotherapy is the use of drugs to destroy unhealthy cells, usually by ending those cells ability to grow and divide. Immunotherapy is designed to boost the body’s natural defenses to fight MDS. It uses materials made either by the body or in a laboratory to improve, target, or restore immune system function. On the basis of drug class, the global Myelodysplastic Syndrome Treatment Market is categorized into cytotoxic antibiotics, topoisomerase inhibitors, alkylating agents and others.
Myelodysplastic Syndrome Treatment Market: Regional Insight
Geographically, North America dominates the global myelodysplastic syndrome treatment market. The U.S. drives the growth in the North America region as it is the largest market in the region due to the rise in healthcare expenditure and increasing demand for myelodysplastic syndrome treatment by the end users in this country. Asia Pacific myelodysplastic syndrome treatment market is the fastest growing market, owing to the increasing prevalence of this disease. The Asia-pacific region offers a substantial potential for market growth due to the increasing number of patients with blood marrow disorder and rapid growth in markets such as India and China.
Myelodysplastic Syndrome Treatment Market: Competitive Analysis
Some of the industry participants of the global Myelodysplastic Syndrome Treatment Market are Bellicum Pharmaceuticals, Inc., Eli Lilly and Company, Celator Pharmaceuticals, Inc., Celgene Corporation, BioLineRx, Novartis AG, Cornerstone Pharmaceuticals Inc., GlaxoSmithKline plc., Acceleron Pharma, Inc., and Amgen Inc. among the others.
Reasons to Buy this Report:
- Comprehensive analysis of global as well as regional markets of the Myelodysplastic Syndrome.
- Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2024.
- Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
- Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.